Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE).
about
Role of nitric oxide in the pathogenesis of Barrett's-associated carcinogenesisAdvances in targeted therapies and new promising targets in esophageal cancerBOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia.The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cellsEmerging optical methods for surveillance of Barrett's oesophagusBile acids down-regulate caveolin-1 in esophageal epithelial cells through sterol responsive element-binding proteinBiomarkers of Barrett's esophagus.Esophageal Helicobacter pylori colonization aggravates esophageal injury caused by reflux.TNF-α and LPA promote synergistic expression of COX-2 in human colonic myofibroblasts: role of LPA-mediated transactivation of upregulated EGFR.Review: Experimental models for Barrett's esophagus and esophageal adenocarcinomaThe prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma.DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclassesTNF-α induces upregulation of EGFR expression and signaling in human colonic myofibroblasts.The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.Color-matched and fluorescence-labeled esophagus phantom and its applications.Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancerGERD-Barrett-Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?HDM2 regulation by AURKA promotes cell survival in gastric cancer.Molecular imaging for guiding oncologic prognosis and therapy in esophageal adenocarcinoma.Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process.Imaging EGFR and HER2 by PET and SPECT: a review.Endosialin and Associated Protein Expression in Soft Tissue Sarcomas: A Potential Target for Anti-Endosialin Therapeutic Strategies.EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.Synthesis and characterization of anti-EGFR fluorescent nanoparticles for optical molecular imaging.The role of nitric oxide in the induction of caudal-type homeobox 2 through epidermal growth factor receptor in the development of Barrett's esophagus.hERG1 behaves as biomarker of progression to adenocarcinoma in Barrett's esophagus and can be exploited for a novel endoscopic surveillance.Subcellular localization of EGFR in esophageal carcinoma cell lines.Identification of the putative intestinal stem cell marker doublecortin and CaM kinase-like-1 in Barrett's esophagus and esophageal adenocarcinoma.Inducible nitric oxide synthase (iNOS) and nitric oxide (NO) are important mediators of reflux-induced cell signalling in esophageal cells.Intraluminal pH and goblet cell density in Barrett's esophagus.Genome-Wide Analysis of Barrett's Adenocarcinoma. A First Step Towards Identifying Patients at Risk and Developing Therapeutic Paths.[Barrett's esophagus. An update].Prognostic impact and potential interaction of EGFR and c-Met in the progression of esophageal squamous cell carcinoma.
P2860
Q26766641-B6231EB2-2841-4C26-BC95-0B33BA2748F2Q26825957-3B206240-84F8-4FEB-9BB8-A42678F109B4Q27332349-D4F66668-24EB-454A-A8D4-13D660E310A7Q27851718-37D71E92-3B72-4FF7-92EF-6317DB96710EQ28082600-0D3BC02F-8EBD-4454-AB73-AEA40B178DE2Q33636583-8D326862-45F9-442E-AB35-829589F161A4Q34448115-60DE546E-C970-4026-ACF4-04AEC1E70F1EQ34499101-FD2A22FC-DAFB-4B45-BA86-836299FF5DEEQ34729143-5E3F6844-C3FD-4F90-BE90-B210FC0F3917Q35235311-0905757E-6A89-45CA-BFA9-D211C650A5F7Q35624456-24D66B92-B66A-4A36-928E-4D3458AF78D7Q35667377-AB6E1D83-CDB4-4D71-A368-06F2C0491C4FQ35970190-6580AA5D-524F-4E24-9840-0177AF37D8C5Q36472693-26A6C314-23DF-4926-B8FB-A4D634A741BFQ36602406-2B766227-CAB4-4ADF-994E-19E652A48249Q36714384-6CB5CD0E-F9AA-419B-B1FC-9220D6BDB87DQ36737638-C7A3D6E0-320C-407B-BB92-98C0D7B8BFF1Q37626244-43E750EF-3C86-4161-93E1-E9312FCB23CFQ37876081-8AC34667-8A00-4C24-88AE-9D5E2CC2B51DQ38005810-4454F281-A841-4CDC-86DA-A29DD4473EC4Q38137829-CDA0D043-C4DF-475A-86DA-8D5DD5D35468Q38330549-2936611E-2416-4C0E-A11B-0BD1B0350B1EQ38392935-6C720007-ED25-4D87-A32A-59741572E2DDQ38970911-343696B2-E434-4223-8978-36F2ABD43442Q39219348-6DE194F5-5B77-4915-81F6-C8B5DAD248F0Q39307834-CCF6ACEA-D5A2-4A90-8D74-BB939B72E65FQ39495923-95E91FF7-4848-4043-B856-74EA630A022EQ40784649-B69E93B9-60A8-483A-BCC8-249458254C44Q41954921-8A58CF26-A225-4687-8393-EAB3FB187DDAQ42510050-FD5AAE38-7D71-4FC0-81EA-1274493DDACDQ46390120-837C11A6-F850-4FE5-A874-9E1037053D52Q47338470-2242A957-9685-4A6A-8FAA-71DB322CEB52Q53095026-9D26D758-B36A-47AF-8383-AD67FA4EFA6FQ55031644-5FE05D12-ED49-4FD2-B114-F8FD7079313F
P2860
Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE).
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Epidermal growth factor recept ...... n in Barrett's esophagus (BE).
@en
type
label
Epidermal growth factor recept ...... n in Barrett's esophagus (BE).
@en
prefLabel
Epidermal growth factor recept ...... n in Barrett's esophagus (BE).
@en
P2093
P2860
P921
P356
P1476
Epidermal growth factor recept ...... on in Barrett's esophagus (BE)
@en
P2093
Antonios Danikas
Chris Tselepis
Elizabeth McAdam
James Manson
John Baxter
Linzi Thomas
Paul Griffiths
P2860
P356
10.1038/AJG.2010.433
P407
P577
2010-12-14T00:00:00Z